| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 223 | 42 |
| Depreciation and amortization of intangible assets | 918 | 612 |
| Amortization and write-off of debt premiums, discounts and issuance costs | 72 | 56 |
| Asset impairments | 1 | 0 |
| Acquisition-related contingent consideration | -72 | -40 |
| Allowances for losses on trade receivable and inventories | 48 | 36 |
| Deferred income taxes | -75 | -51 |
| Net gain on sale of assets | 6 | 0 |
| Adjustments to accrued legal settlements | -40 | -5 |
| Payments of accrued legal settlements | 198 | 106 |
| Share-based compensation | 132 | 89 |
| Gain excluded from hedge effectiveness | 8 | 6 |
| Gain on extinguishment of debt | 181 | 178 |
| Payments of contingent consideration adjustments, including accretion | 6 | 4 |
| Amortization of interim contract and inventory step-up resulting from acquisitions | 62 | 42 |
| Foreign exchange and other | 18 | 23 |
| Trade receivables | 199 | -19 |
| Inventories | 7 | 23 |
| Prepaid expenses and other current assets | 29 | 34 |
| Accounts payable, accrued and other liabilities | 208 | 64 |
| Net cash provided by operating activities | 905 | 500 |
| Acquisitions and other investments | 17 | 12 |
| Purchases of property, plant and equipment | 305 | 214 |
| Acquisition of intangible assets and other assets | 10 | 10 |
| Purchases of marketable securities | 6 | 5 |
| Proceeds from sale of marketable securities | 6 | 5 |
| Proceeds from sale of assets and businesses, net of costs to sell | 7 | 0 |
| Interest settlements from cross-currency swaps | -12 | -6 |
| Net cash used in investing activities | -313 | -230 |
| Issuance of long-term debt, net of discounts | 10,421 | 10,422 |
| Repayments of long-term debt | 10,839 | 10,135 |
| Payments of employee withholding taxes related to share-based awards | 24 | 19 |
| Payments of acquisition-related contingent consideration | 18 | 12 |
| Payments of financing costs | 38 | 36 |
| Other | -9 | -8 |
| Net cash used in financing activities | -507 | 212 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 54 | 60 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 139 | 542 |
| Cash and cash equivalents at beginning of period | 1,201 | - |
| Cash and cash equivalents at end of period | 1,340 | - |
Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc. (BHC)